Related Experiment Video
Updated: Feb 19, 2026
08:24
Injections of Lipopolysaccharide into Mice to Mimic Entrance of Microbial-derived Products After Intestinal Barrier Breach
Published on: May 2, 2018
20.6K
GLP-1 agonists and the gut microbiome: A bidirectional relationship
Srinivas Kamath1, Nicole S L Chan1, Paul Joyce1
1School of Pharmacy and Biomedical Science, Adelaide University, Adelaide, South Australia, Australia.
British Journal of Clinical Pharmacology
|February 18, 2026
Summary
Glucagon-like peptide-1 (GLP-1) receptor agonists impact gut bacteria, which in turn influence GLP-1 secretion. Understanding this gut microbiome interaction is key for personalized diabetes and obesity treatments.
Area of Science:
- Pharmacology and Metabolic Research
- Microbiome Science
- Incretin Biology
Background:
- Glucagon-like peptide-1 (GLP-1) receptor agonists are vital for type 2 diabetes mellitus (T2DM) and obesity management.
- The gut microbiome's role in GLP-1 dynamics and therapeutic response is an emerging research area.
- Microbial metabolites influence GLP-1 secretion, and GLP-1 agonists modulate gut microbial composition.
Purpose of the Study:
- To review the current evidence on microbiome-mediated modulation of GLP-1 dynamics.
- To evaluate the pharmacomicrobiomic effects of GLP-1 agonists.
- To outline future research directions at the gut microbiota-incretin axis interface.
Main Methods:
- Literature review of studies on GLP-1, gut microbiota, and metabolic outcomes.
- Analysis of pharmacomicrobiomic interactions and multiomics data.
- Exploration of computational modelling for dissecting host-microbe-drug axis.
Main Results:
- Evidence suggests a bidirectional interplay between the gut microbiome and GLP-1 signaling.
- Gut microbial signatures may predict variability in GLP-1 agonist response.
- Microbiome composition influences metabolic outcomes beyond incretin effects.
Conclusions:
- The host-microbe-drug axis is crucial for understanding GLP-1 agonist action.
- Personalized metabolic medicine may leverage microbiome context for optimizing GLP-1 therapies.
- Future research should address confounders like diet and host genetics for causative mechanism elucidation.
Related Concept Videos
01:24Glucagon-like Receptor Agonists
1.0K
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
1.0K
01:50What is Monogastric Digestion?
76.0K
The human body contains a monogastric digestive system. In a monogastric digestive system, the stomach only contains one chamber in which it digests food. Several other animal species also have monogastric digestive systems, including pigs, horses, dogs, and birds. This chapter, however, focuses on the human digestive system.
76.0K
01:23Drugs Affecting GI Tract Motility: Serotonin Receptor Agonists
1.1K
Serotonin, a crucial neurotransmitter synthesized by enterochromaffin cells, plays a cardinal role in regulating gastrointestinal (GI) motility. With over 90% of the body's total serotonin in the GI tract, its influence on digestive processes is profound. Serotonin is swiftly released upon various stimuli, such as food boluses or certain drugs, triggering intrinsic sensory neurons in the myenteric plexus and extrinsic vagal and spinal sensory neurons. This leads to the activation of the...
1.1K
01:19Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
615
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
615
01:29Bacterial Flora of the Large Intestine
1.7K
The gut microbiome is formed by a vast and diverse community of bacteria that colonizes our large intestine. These bacteria start residing in the gut from birth and continue diversifying throughout life, influenced by factors such as diet, lifestyle, and stress. The gut bacterial community also includes bacteria from food and those that enter the colon through the anus.
The normal gut flora of the colon plays a critical role in generating essential vitamins such as vitamins K, B5, and B7.
The normal gut flora of the colon plays a critical role in generating essential vitamins such as vitamins K, B5, and B7.
1.7K
01:21Drugs for Treatment of Constipation-Predominant IBS
915
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
915